Bio-Path Holdings Files 8-K
Ticker: BPTH · Form: 8-K · Filed: Aug 21, 2024 · CIK: 1133818
| Field | Detail |
|---|---|
| Company | Bio-Path Holdings, Inc. (BPTH) |
| Form Type | 8-K |
| Filed Date | Aug 21, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, 8-k
Related Tickers: BPTH
TL;DR
BPTH filed a routine 8-K, no major news.
AI Summary
Bio-Path Holdings, Inc. filed an 8-K on August 21, 2024, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or material events beyond the standard reporting requirements.
Why It Matters
This filing indicates Bio-Path Holdings, Inc. is meeting its regulatory reporting obligations with the SEC, which is standard for publicly traded companies.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for regulatory compliance and does not disclose any new material events or financial information that would inherently increase risk.
Key Players & Entities
- BIO-PATH HOLDINGS, INC. (company) — Registrant
- August 21, 2024 (date) — Report Date
- Delaware (jurisdiction) — State of Incorporation
- 77401 (zip_code) — Business Address Zip Code
FAQ
What is the primary purpose of this 8-K filing for Bio-Path Holdings, Inc.?
The primary purpose of this 8-K filing is for Regulation FD Disclosure and to report Financial Statements and Exhibits, as indicated in the filing details.
On what date was this 8-K report filed?
This 8-K report was filed on August 21, 2024.
What is the state of incorporation for Bio-Path Holdings, Inc.?
Bio-Path Holdings, Inc. is incorporated in Delaware.
What is the principal executive office address for Bio-Path Holdings, Inc.?
The principal executive offices are located at 4710 Bellaire Boulevard, Suite 210, Bellaire, Texas 77401.
Does this filing report any specific material events or financial results?
No, this filing primarily serves as a regulatory disclosure and reports financial statements and exhibits without detailing specific new material events or financial results.
Filing Stats: 438 words · 2 min read · ~1 pages · Grade level 10.7 · Accepted 2024-08-21 16:15:26
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share BPTH The Nasdaq Capital M
Filing Documents
- bpth-20240821x8k.htm (8-K) — 38KB
- bpth-20240821xex99d1.htm (EX-99.1) — 22KB
- bpth-20240821xex99d1001.jpg (GRAPHIC) — 11KB
- 0001558370-24-012413.txt ( ) — 198KB
- bpth-20240821.xsd (EX-101.SCH) — 3KB
- bpth-20240821_lab.xml (EX-101.LAB) — 16KB
- bpth-20240821_pre.xml (EX-101.PRE) — 10KB
- bpth-20240821x8k_htm.xml (XML) — 5KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On August 21, 2024, Bio-Path Holdings, Inc. (the "Company") issued a press release titled, "Bio-Path Holdings Reports Solid Tumor Patient Response Supporting BP1001-A's Compelling Potential as Treatment for Advanced Solid Tumors." A copy of such press release is attached hereto as Exhibit 99.1.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits . Exhibit Number Description 99.1 Press release dated August 21, 2024. 104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL (included as Exhibit 101).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this Current Report to be signed on its behalf by the undersigned hereunto duly authorized. BIO-PATH HOLDINGS, INC. Dated: August 21, 2024 By: /s/ Peter H. Nielsen Peter H. Nielsen President and Chief Executive Officer